Blockchain is the future of cancer prevention

From this article you will learn how Luven Diagnostic brings the future to cancer detection and treatment using blockchain technology
08 December 2017   992

Cancer is the most deadly disease in the developed world as one in three people develop cancer during their lifetime. Regardless of the rapid development of modern medicine and biology, cancer takes millions of human lives. The key to successful cancer treatment is early diagnosis. If detected at the early stage, when there are no visible symptoms, cancer can be cured without any complex aggressive therapies. Luven Diagnostic is an ongoing project based on a cancer diagnostic technology designed to save millions of lives.

What is Luven Diagnostic?

The Luven screening test method created by scientists of Luven Diagnostic company is designed to detect cancer at its early stages with the accuracy of up to 96% only comparable to biopsy. None of the existing diagnostic techniques has such a high diagnostic accuracy. The Luven technology allows to diagnose the disease at its early stages, thus, giving a chance to thousands of people to prevent its further development. Luven can recognize the progressive disease when other diagnostic methods are helpless.

Luven Diagnostic Method Overview

  • The development of this method started in early 1983 at the research institute, chair for genetics. Based on the cellular theory by Rudolf Vichow, a team of scientists was working on a diagnostic method and studying buccal cells.
  • A new diagnostic method was born in 2004, according to which any changes in the human body reflect on cells, including buccal epithelial cells.
  • The Luven Diagnostic allows, with a high degree of accuracy, to detect oncological diseases, localization of a diseased organ, tendency of progression of the disease and comorbidities.
  • In order to have the disease detected, the patient undergoes a special diagnostic procedure and a specially developed program makes a printable report, which provides the data upon cancer lesions in the body, if there are any, the redisposition or liability to cancer and comorbidities according to the international classification of diseases.

Luven Diagnostic Method in numbersLuven Diagnostic in numbers

How does Luven Diagnostic Test work?

Diagnostic procedure:

  • A patient card is filled out in the computer program
  • A buccal swab is carefully collected with a mouth spatula and placed under the microscope
  • The program records a video from the microscope and transfers it to the processing center
  • Within several minutes the program receives a printable report

Based on data processing results the report shows:

  • Cancer lesions in the body, if any
  • Predisposition or liability to cancer
  • Comorbidities according to the international classification of diseases (ICD-10 and TNM)

Luven Diagnostic Token Sale Information

Sales dates. Pre-ICO. From Dec 12, 2017 to Dec 29, 2017
ICO. From Jan 15, 2018 to Feb 28, 2018

Accepted currencies. ETH, BTC
Token exchange rate. 1 ETH = 290 tokens

Hard capPre-ICO. 3,000,000 tokens
Bonuses. 1st day bonus – 30%
1st week bonus – 25%
2nd week bonus – 20%
3d week bonus – 15%
ICO. 27,000,000 tokens
Bonuses. 1st week – 10%

Luven Diagnostic allocation of fundsLuven Diagnostic Allocation of funds

Luven Diagnostic Investment Prospects

Token holders have two opportunities:

  • to receive a part of the company income
  • to exchange the tokens for testing services with a 30% discount, using or selling them to wholesale customers (such as clinics, insurance companies, physicians in private practice etc.)

Luven Diagnostic Business Benefits

  • A lucrative market
    A pre-clinical cancer diagnosis market is growing rapidly due to fear of the dreaded disease.
  • Service demand
    Health care and healthy lifestyle is one of the most popular trends among youngsters and elderly people which ensures success of Luven business.
  • Short payback period
    Due to 100% gross margin of the service, our partners will recover their investments during the first two months.
  • Specialty of the service
    Luven Diagnostic is a unique patented method for early cancer detection, localization of the disease and is fast and absolutely painless.
  • A broad spectrum of potential customers
    Literally everyone in this world is a potential customer. Cancer is beyond any boundaries, age or status. Subsequently, everyone can be a target audience.


  • Whitepaper

More Information

  • Website
  • Medium
  • Twitter
  • Facebook
  • LinkedIn
  • Bitcointalk
  • Instagram

Tezos Co-Founder penaltied by Wall Street Regulator

Tezos co-founder Arthur Breitman is punished with a fine and a trading veto for two years by The Financial Industry Regulatory Authority (FINRA)
20 April 2018   93

The Wall Street regulatory institution has come to a adjudgement with Breitman after he was indicted of producing false statements about his side venture (Tezos) while he was actually employed at Morgan Stanley. All registered FINRA securities specialists are demanded to report any for-profit activity outside of their stated employment if there is “reasonable expectation of compensation.”

The regulatory activity started from a Reuters article published in October that discovered Breitman, who is filed with FINRA as a French citizen, never disclosed hise work for Tezos while still employed at Morgan Stanley within the years of 2014-2015.

Together with the other proofs published in Reuters` article is a business plan written in 2015 that lists Brietmen as chief executive and makes projections on the potential for the company to be worth as much as 20 billion dollars over 15 years.  They also cited two papers Breitman penned under the pseudonym L.M. Goodman about Tezos, showing that he purposely hid his connection with the firm.

FINRA enclosed that “Breitman did not notify Morgan Stanley at any time that he was engaging in these outside business activities.” The adjudgement conditions of April 18 are that Breitman shun any broker-deals for 2 years and pay a $20,000 fine. Breitman neither accept nor disclaim the indictments.

The settlement with FINRA is unrelated to and has no impact on the launch of the Tezos network. Arthur cooperated fully with FINRA at all times and Arthur is pleased to put this personal matter behind him.
Sarah Lightdale, lawyer of Arthur Breitman

Last July the Tezos foundation increased for $232 million from their initial coin offering to found the blockchain network for smart contracts but still haven’t delivered any of the cryptocurrency to supporters because of infighting and legal problems in and outside of the boardroom.